FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972054549> ?p ?o ?g. }

• W1972054549 endingPage "719" @default.
• W1972054549 startingPage "719" @default.
• W1972054549 abstract "Many high-risk coronary heart disease (CHD) patients on statin monotherapy do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals, and combination lipid-lowering therapy may be considered for these individuals. The effect of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin therapy versus titrating these statins on LDL-C changes and goal attainment in CHD or CHD risk-equivalent patients was assessed in a large, managed-care database in the US.Eligible patients (n=17,830), initially on statin monotherapy who were ≥18 years with baseline and follow-up LDL-C values, no concomitant use of other lipid-lowering therapy, and on lipid-lowering therapy for ≥42 days, were identified between November 1, 2002 and September 30, 2009. The percent change from baseline in LDL-C levels and the odds ratios for attainment of LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) were estimated using an analysis of covariance and logistic regression, respectively, adjusted for various baseline factors.LDL-C reductions from baseline and goal attainment improved substantially in patients treated with ezetimibe added onto simvastatin, atorvastatin, or rosuvastatin therapy (n=2,312) versus those (n=13,053) who titrated these statins. In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins.CHD/CHD risk-equivalent patients in a large US managed-care database, who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin, had greater LDL-C reductions and goal attainment than those who uptitrated these statin therapies. Our study suggests that high-risk CHD patients in need of more intensive LDL-C lowering therapy may benefit by adding ezetimibe onto statin therapy." @default.
• W1972054549 created "2016-06-24" @default.
• W1972054549 creator A5001385286 @default.
• W1972054549 creator A5033223903 @default.
• W1972054549 creator A5036509509 @default.
• W1972054549 creator A5040420889 @default.
• W1972054549 creator A5046066860 @default.
• W1972054549 creator A5047389114 @default.
• W1972054549 creator A5054876477 @default.
• W1972054549 creator A5066354341 @default.
• W1972054549 creator A5090460841 @default.
• W1972054549 date "2013-11-01" @default.
• W1972054549 modified "2023-09-23" @default.
• W1972054549 title "Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy" @default.
• W1972054549 cites W1970799753 @default.
• W1972054549 cites W1972661406 @default.
• W1972054549 cites W1974768421 @default.
• W1972054549 cites W1976212953 @default.
• W1972054549 cites W1977399475 @default.
• W1972054549 cites W1981798840 @default.
• W1972054549 cites W1984259359 @default.
• W1972054549 cites W1984387917 @default.
• W1972054549 cites W1985258577 @default.
• W1972054549 cites W1991429317 @default.
• W1972054549 cites W2008356419 @default.
• W1972054549 cites W2025690892 @default.
• W1972054549 cites W2027316231 @default.
• W1972054549 cites W2037413341 @default.
• W1972054549 cites W2043903046 @default.
• W1972054549 cites W2061398329 @default.
• W1972054549 cites W2062693500 @default.
• W1972054549 cites W2067231723 @default.
• W1972054549 cites W2073896718 @default.
• W1972054549 cites W2082036057 @default.
• W1972054549 cites W2103825268 @default.
• W1972054549 cites W2106343349 @default.
• W1972054549 cites W2119355774 @default.
• W1972054549 cites W2132401646 @default.
• W1972054549 cites W2134120087 @default.
• W1972054549 cites W2135961993 @default.
• W1972054549 cites W2138675504 @default.
• W1972054549 cites W2141773571 @default.
• W1972054549 cites W2145866410 @default.
• W1972054549 cites W2147980803 @default.
• W1972054549 cites W2154704322 @default.
• W1972054549 cites W2161253919 @default.
• W1972054549 cites W2164089346 @default.
• W1972054549 cites W2167045683 @default.
• W1972054549 doi "https://doi.org/10.2147/vhrm.s49840" @default.
• W1972054549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3833706" @default.
• W1972054549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24265554" @default.
• W1972054549 hasPublicationYear "2013" @default.
• W1972054549 type Work @default.
• W1972054549 sameAs 1972054549 @default.
• W1972054549 citedByCount "28" @default.
• W1972054549 countsByYear W19720545492014 @default.
• W1972054549 countsByYear W19720545492015 @default.
• W1972054549 countsByYear W19720545492016 @default.
• W1972054549 countsByYear W19720545492017 @default.
• W1972054549 countsByYear W19720545492018 @default.
• W1972054549 countsByYear W19720545492019 @default.
• W1972054549 countsByYear W19720545492020 @default.
• W1972054549 countsByYear W19720545492021 @default.
• W1972054549 countsByYear W19720545492022 @default.
• W1972054549 crossrefType "journal-article" @default.
• W1972054549 hasAuthorship W1972054549A5001385286 @default.
• W1972054549 hasAuthorship W1972054549A5033223903 @default.
• W1972054549 hasAuthorship W1972054549A5036509509 @default.
• W1972054549 hasAuthorship W1972054549A5040420889 @default.
• W1972054549 hasAuthorship W1972054549A5046066860 @default.
• W1972054549 hasAuthorship W1972054549A5047389114 @default.
• W1972054549 hasAuthorship W1972054549A5054876477 @default.
• W1972054549 hasAuthorship W1972054549A5066354341 @default.
• W1972054549 hasAuthorship W1972054549A5090460841 @default.
• W1972054549 hasBestOaLocation W19720545491 @default.
• W1972054549 hasConcept C104950815 @default.
• W1972054549 hasConcept C126322002 @default.
• W1972054549 hasConcept C126894567 @default.
• W1972054549 hasConcept C134651460 @default.
• W1972054549 hasConcept C156957248 @default.
• W1972054549 hasConcept C181199279 @default.
• W1972054549 hasConcept C185592680 @default.
• W1972054549 hasConcept C2776329913 @default.
• W1972054549 hasConcept C2776839432 @default.
• W1972054549 hasConcept C2776999253 @default.
• W1972054549 hasConcept C2777482532 @default.
• W1972054549 hasConcept C2778657065 @default.
• W1972054549 hasConcept C2780499067 @default.
• W1972054549 hasConcept C2908737378 @default.
• W1972054549 hasConcept C55493867 @default.
• W1972054549 hasConcept C71924100 @default.
• W1972054549 hasConcept C98274493 @default.
• W1972054549 hasConceptScore W1972054549C104950815 @default.
• W1972054549 hasConceptScore W1972054549C126322002 @default.
• W1972054549 hasConceptScore W1972054549C126894567 @default.
• W1972054549 hasConceptScore W1972054549C134651460 @default.
• W1972054549 hasConceptScore W1972054549C156957248 @default.
• W1972054549 hasConceptScore W1972054549C181199279 @default.

• next